UPM Pharmaceuticals operates a comprehensive contract development and manufacturing organization from its state-of-the-art 475,000-square-foot facility in Bristol, Tennessee. With over 100 years of continuous pharmaceutical manufacturing heritage at this location, UPM has evolved into a leading CDMO specializing in oral solid dose and semi-solid pharmaceutical products. The company excels in manufacturing capsules, tablets, creams, and ointments, with impressive production capacity reaching 700 million capsules, 4 billion tablets, and 1.3 million kilograms of semi-solids annually.
UPM Pharmaceuticals distinguishes itself through expertise in handling potent compounds, hormones, and DEA-licensed controlled substances across Schedules I through V. The facility features dedicated low-humidity manufacturing suites and specialized containment capabilities for high-potency active pharmaceutical ingredients. Their comprehensive services span the entire product lifecycle, from formulation development and analytical method development to cGMP manufacturing, packaging, and stability testing.
The Bristol facility has successfully advanced over 80 compounds from proof of concept to full commercialization, demonstrating their capability to scale from development through large-scale commercial production. UPM combines the resources and scale of a major pharmaceutical manufacturer with the agility and personalized service of a family-owned business, having operated under the same family leadership for more than 25 years. Their manufacturing processes encompass pharmaceutical blending, compression, encapsulation, tableting, coating, drying, and granulation technologies.
Specialties: CDMO ServicesSemi-solid PreparationsSolid Dose +1 more
Processes: Formulation developmentContract manufacturing +2 more